Cost of Revenue Trends: Johnson & Johnson vs Exelixis, Inc.

Cost of Revenue: A Tale of Two Companies

In the ever-evolving landscape of the pharmaceutical industry, understanding cost dynamics is crucial. Johnson & Johnson, a stalwart in the sector, has consistently maintained a high cost of revenue, peaking at approximately $26.6 billion in 2023. This represents a steady increase of around 17% from 2014. In contrast, Exelixis, Inc., a burgeoning biotech firm, has seen its cost of revenue skyrocket by over 3,400% during the same period, reaching about $72.5 million in 2023.

A Decade of Growth and Challenges

From 2014 to 2023, Johnson & Johnson's cost of revenue reflects its expansive operations and market dominance. Meanwhile, Exelixis's dramatic rise underscores its aggressive growth strategy and increasing market presence. This comparison highlights the diverse strategies and challenges faced by established giants and emerging players in the pharmaceutical industry.